Anaxirone
Term · Oncology and biomedicine · MLC-T-ONC-010056
A synthetic triepoxide alkylating agent with potential antineoplastic activity. Anaxirone alkylates DNA via actual or derived epoxide groups, resulting in inhibition of DNA synthesis. This agent has been shown to exhibit a broad spectrum of antineoplastic activity against experimental tumors, including those resistant to other alkylating agents.
| Identifier | MLC-T-ONC-010056 |
|---|---|
| Field | Oncology and biomedicine |
| Abbreviation | TGU |
| Synonyms | triglycidylurazol |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-010056",
"term": "Anaxirone",
"field": "Oncology and biomedicine",
"definition": "A synthetic triepoxide alkylating agent with potential antineoplastic activity. Anaxirone alkylates DNA via actual or derived epoxide groups, resulting in inhibition of DNA synthesis. This agent has been shown to exhibit a broad spectrum of antineoplastic activity against experimental tumors, including those resistant to other alkylating agents.",
"abbreviation": "TGU",
"synonyms": [
"triglycidylurazol"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/anaxirone/"
}
Record 1,055 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.